A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Active, not recruiting · Phase 3 · NCT04576156
Conditions: Myelofibrosis
At a glance
- Research payments reported, 2025
- $484,779
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 327
About the trial
- Sponsor
- Geron Corporation
- Tested
- Imetelstat (drug), Best Available Therapy (BAT) (drug)
- Dates
- Started 2021-04-12; completion 2028-06-30
- Results posted
- Not yet
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
From ClinicalTrials.gov, last updated 2026-07-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Geron Corporation reported $484,779 in research payments for this study in 2025 (363 payments).
Products named: Imetelstat
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael Y. Choi, M.D. Hematology & Oncology · San Diego, CA
- Gary J. Schiller, MD Hematology & Oncology · Los Angeles, CA
- Nikolai A. Podoltsev, M.D., PH.D. Hematology · New Haven, CT
- Rami S. Komrokji, M.D. Hematology · Tampa, FL
- Jason Tache, D.O. Hematology & Oncology · Plantation, FL
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Cheryl A. Sadow, MD Radiology · Boston, MA
- Vikram A. Sahni, M.D. Radiology · Wellesley, MA
- Nisha I. Sainani, M.D. Radiology · Boston, MA
- Lindsay A. Rein, M.D. Hematology · Durham, NC
- John Mascarenhas, MD Hematology & Oncology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Icahn School of Medicine at Mount Sinai $113,564
- H Lee Moffitt Cancer Center and Research Institute Hospital Inc $108,339
- Ronald Reagan UCLA Medical Center, CA $79,808
- Norton Healthcare Inc $57,862
- The Regents of the University of California $36,979
- Duke University $34,043
- Yale University $21,804
- Brcr Medical Center Inc $17,079
- Peritus Imaging Inc $11,100
- Vx3 Imaging PC $2,550
- Ns Imaging Related Services Inc $1,650
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.